(R)-1-(3,4-Dimethoxyphenyl)ethanamine

Cat.NO.:A290247 Purity:95%

Product Details of [ 100570-24-9 ]

CAS No. :	100570-24-9
Formula :	C₁₀H₁₅NO₂
M.W :	181.23
SMILES Code :	N[C@@H](C1=CC=C(OC)C(OC)=C1)C
MDL No. :	MFCD06761897
InChI Key :	OEPFPKVWOOSTBV-SSDOTTSWSA-N
Pubchem ID :	793783

Safety of [ 100570-24-9 ]

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H302-H315-H318
Precautionary Statements:	P264-P270-P280-P302+P352-P305+P351+P338-P310-P330-P362+P364-P403-P501

Computational Chemistry of [ 100570-24-9 ] Show Less

Physicochemical Properties

Num. heavy atoms	13
Num. arom. heavy atoms	6
Fraction Csp3	0.4
Num. rotatable bonds	3
Num. H-bond acceptors	3.0
Num. H-bond donors	1.0
Molar Refractivity	51.91
TPSA ? Topological Polar Surface Area: Calculated from Ertl P. et al. 2000 J. Med. Chem.	44.48 Å²

Lipophilicity

Log P_o/w (iLOGP)? iLOGP: in-house physics-based method implemented from Daina A et al. 2014 J. Chem. Inf. Model.	2.18
Log P_o/w (XLOGP3)? XLOGP3: Atomistic and knowledge-based method calculated by XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry	0.98
Log P_o/w (WLOGP)? WLOGP: Atomistic method implemented from Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.	1.4
Log P_o/w (MLOGP)? MLOGP: Topological method implemented from Moriguchi I. et al. 1992 Chem. Pharm. Bull. Moriguchi I. et al. 1994 Chem. Pharm. Bull. Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.	1.22
Log P_o/w (SILICOS-IT)? SILICOS-IT: Hybrid fragmental/topological method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	1.62
Consensus Log P_o/w? Consensus Log P_o/w: Average of all five predictions	1.48

Water Solubility

Log S (ESOL):? ESOL: Topological method implemented from Delaney JS. 2004 J. Chem. Inf. Model.	-1.72
Solubility	3.42 mg/ml ; 0.0189 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (Ali)? Ali: Topological method implemented from Ali J. et al. 2012 J. Chem. Inf. Model.	-1.5
Solubility	5.7 mg/ml ; 0.0315 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Very soluble
Log S (SILICOS-IT)? SILICOS-IT: Fragmental method calculated by FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com	-2.73
Solubility	0.338 mg/ml ; 0.00187 mol/l
Class? Solubility class: Log S scale Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly	Soluble

Pharmacokinetics

GI absorption? Gatrointestinal absorption: according to the white of the BOILED-Egg	High
BBB permeant? BBB permeation: according to the yolk of the BOILED-Egg	Yes
P-gp substrate? P-glycoprotein substrate: SVM model built on 1033 molecules (training set) and tested on 415 molecules (test set) 10-fold CV: ACC=0.72 / AUC=0.77 External: ACC=0.88 / AUC=0.94	No
CYP1A2 inhibitor? Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.83 / AUC=0.90 External: ACC=0.84 / AUC=0.91	No
CYP2C19 inhibitor? Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set) and tested on 3000 molecules (test set) 10-fold CV: ACC=0.80 / AUC=0.86 External: ACC=0.80 / AUC=0.87	No
CYP2C9 inhibitor? Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set) and tested on 2075 molecules (test set) 10-fold CV: ACC=0.78 / AUC=0.85 External: ACC=0.71 / AUC=0.81	No
CYP2D6 inhibitor? Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set) and tested on 1068 molecules (test set) 10-fold CV: ACC=0.79 / AUC=0.85 External: ACC=0.81 / AUC=0.87	No
CYP3A4 inhibitor? Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set) and tested on 2579 molecules (test set) 10-fold CV: ACC=0.77 / AUC=0.85 External: ACC=0.78 / AUC=0.86	No
Log Kp (skin permeation)? Skin permeation: QSPR model implemented from Potts RO and Guy RH. 1992 Pharm. Res.	-6.71 cm/s

Druglikeness

Lipinski? Lipinski (Pfizer) filter: implemented from Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev. MW ≤ 500 MLOGP ≤ 4.15 N or O ≤ 10 NH or OH ≤ 5	0.0
Ghose? Ghose filter: implemented from Ghose AK. et al. 1999 J. Comb. Chem. 160 ≤ MW ≤ 480 -0.4 ≤ WLOGP ≤ 5.6 40 ≤ MR ≤ 130 20 ≤ atoms ≤ 70	None
Veber? Veber (GSK) filter: implemented from Veber DF. et al. 2002 J. Med. Chem. Rotatable bonds ≤ 10 TPSA ≤ 140	0.0
Egan? Egan (Pharmacia) filter: implemented from Egan WJ. et al. 2000 J. Med. Chem. WLOGP ≤ 5.88 TPSA ≤ 131.6	0.0
Muegge? Muegge (Bayer) filter: implemented from Muegge I. et al. 2001 J. Med. Chem. 200 ≤ MW ≤ 600 -2 ≤ XLOGP ≤ 5 TPSA ≤ 150 Num. rings ≤ 7 Num. carbon > 4 Num. heteroatoms > 1 Num. rotatable bonds ≤ 15 H-bond acc. ≤ 10 H-bond don. ≤ 5	1.0
Bioavailability Score? Abbott Bioavailability Score: Probability of F > 10% in rat implemented from Martin YC. 2005 J. Med. Chem.	0.55

Medicinal Chemistry

PAINS? Pan Assay Interference Structures: implemented from Baell JB. & Holloway GA. 2010 J. Med. Chem.	0.0 alert
Brenk? Structural Alert: implemented from Brenk R. et al. 2008 ChemMedChem	0.0 alert: heavy_metal
Leadlikeness? Leadlikeness: implemented from Teague SJ. 1999 Angew. Chem. Int. Ed. 250 ≤ MW ≤ 350 XLOGP ≤ 3.5 Num. rotatable bonds ≤ 7	No; 1 violation:MW<1.0
Synthetic accessibility? Synthetic accessibility score: from 1 (very easy) to 10 (very difficult) based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties, trained on 12’782’590 molecules and tested on 40 external molecules (r² = 0.94)	1.9

Application In Synthesis of [ 100570-24-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Downstream synthetic route of [ 100570-24-9 ]

[ 100570-24-9 ] Synthesis Path-Downstream 1~9

1
[ 108-24-7 ]
N-(4-methoxyphenyl)-1-(3,4-dimethoxyphenyl)ethylamine [ No CAS ]
[ 1205-91-0 ]
[ 100570-24-9 ]
N-[1-(3,4-dimethoxy-phenyl)-ethyl]-acetamide [ No CAS ]

References: [1]Tetrahedron Letters,2000,vol. 41,p. 5533 – 5536.

2
[ 108-24-7 ]
[ 293307-92-3 ]
[ 100570-24-9 ]
N-[1-(3,4-dimethoxy-phenyl)-ethyl]-acetamide [ No CAS ]

References: [1]Tetrahedron Letters,2000,vol. 41,p. 5533 – 5536.

3
[ 293307-92-3 ]
[ 571-60-8 ]
[ 100570-24-9 ]

References: [1]Tetrahedron Letters,2000,vol. 41,p. 5533 – 5536.

4
[ 100570-24-9 ]
[ 390811-94-6 ]
1-cyclohexyl-2-pyridin-2-yl-1H-benzoimidazole-5-carboxylic acid [1-(3,4-dimethoxy-phenyl)-ethyl]-amide [ No CAS ]

References: [1]Bioorganic and Medicinal Chemistry Letters,2004,vol. 14,p. 967 – 971.

5
[1-(3,4-Dimethoxy-phenyl)-meth-(E)-ylidene]-(4-methoxy-naphthalen-1-yl)-amine [ No CAS ]
[ 100570-24-9 ]

References: [1]Tetrahedron Letters,2000,vol. 41,p. 5533 – 5536.
[2]Tetrahedron Letters,2000,vol. 41,p. 5533 – 5536.

6
[ 351-33-7 ]
[ 100570-24-9 ]
[ 875656-36-3 ]

Yield	Reaction Conditions	Operation in experiment
	With triethylamine; In toluene; at 90.0℃; for 3.0h;	Step 2. N-(4-chloro-3-trifluoromethylphenyl)-2-[(R)-l-(3,4-dimethoxyphenyl)-ethylamino]-acetamideA mixture of (R)-l-(3,4-dimethoxyphenyl)-ethylamine (1.5 g, 8.1 mmol, obtained by resolution of the racemic amine with (R)-mandelic acid), 2-chloro-N-(4-chloro-3-trifluoromethylphenyl)-acetamide (2.1g, 7.7 mmol) and triethylamine (3.4 mL, 24 mmol) in toluene (30 mL) is heated at 90C (oil bath temperature) for 3 h. After cooling to room temperature the mixture is poured into water (200 mL) and partitioned into 100 mL of ethyl acetate. The organic layer is dried with MgSO4 and filtered and the solvent removed under reduced pressure. Flash chromatography on silicagel eluting with 5% methanol in ethyl acetate furnishes the title compound as a dry foam. LC/MS: 417 (M+l).

References: [1]Patent: WO2006/15279,2006,A1 .Location in patent: Page/Page column 43-44.

7
[ 50919-08-9 ]
[ 100570-24-9 ]

Yield	Reaction Conditions	Operation in experiment
	With (R)-Mandelic Acid;Resolution of racemate;	A mixture of (R)-l-(3,4-dimethoxyphenyl)-ethylamine (1.5 g, 8.1 mmol, obtained by resolution of the racemic amine with (R)-mandelic acid)

References: [1]Patent: WO2006/15279,2006,A1 .Location in patent: Page/Page column 44.

8
diallyl-[1-(R)-(3,4-dimethoxyphenyl)ethyl]amine [ No CAS ]
[ 100570-24-9 ]

References: [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 7432 – 7445.

9
[ 37418-88-5 ]
[ 100570-24-9 ]
[ 1190089-37-2 ]

References: [1]Journal of Medicinal Chemistry,2009,vol. 52,p. 7432 – 7445.

Details

Reviews

There are no reviews yet.

Be the first to review “(R)-1-(3,4-Dimethoxyphenyl)ethanamine”

Products

(R)-1-(3,4-Dimethoxyphenyl)ethanamine

Product Details of [ 100570-24-9 ]

Safety of [ 100570-24-9 ]

Computational Chemistry of [ 100570-24-9 ] Show Less

Physicochemical Properties

Lipophilicity

Water Solubility

Pharmacokinetics

Druglikeness

Medicinal Chemistry

Application In Synthesis of [ 100570-24-9 ]

[ 100570-24-9 ] Synthesis Path-Downstream 1~9

Details

Reviews

2-((2-Nitrophenyl)sulfonyl)acetonitrile

2-Amino-5-(trifluoromethyl)benzoimidazole

Quick Links

Support Links

Locations